论文部分内容阅读
目的 :揭示 APL患者 ATRA治疗后高白细胞征的机制。方法 :外周血 WBC计数及分类按常规进行。体内外粒 -单系集落 (CFU- GM)按半固体琼脂法进行。ATRA体内实验中的骨髓与脾脏均用 2 0 0目网研磨制成单个细胞悬液后计 WBC数。结果 :ATRA临床治疗 APL 患者可引起明显的 WBC、早幼粒及较成熟粒系升高。CFU- GM呈现升高趋势。而 APL 患者骨髓 CFU- L 逐渐降低。正常小鼠的体内实验中 ,ATRA明显增加其骨髓CFU - GM形成 ,6 0 min时外周 WBC增加 (P<0 .0 5 ) ,单位重量脾 WBC明显减少 ,但骨髓 WBC无明显变化。结论 :ATRA可引起小鼠贮存池 WBC向外周血中分布 ,体内作用 15 d后 ,骨髓 GU - GM升高。但与临床 APL患者 WBC变化的时相不一致。
Objective: To reveal the mechanism of leukocyte levy after ATRA treatment in APL patients. Methods: WBC count and classification of peripheral blood were routinely performed. In vitro and in vivo particle - single colony (CFU-GM) by semi-solid agar method. ATRA in vivo experiments in bone marrow and spleen are used 200 mesh grinding into a single cell suspension count WBC count. Results: ATRA clinical treatment of APL patients can cause significant WBC, promyelocytic and more mature grain increased. CFU-GM showed an upward trend. The APL patients with bone marrow CFU-L gradually decreased. In vivo experiments in normal mice, ATRA significantly increased CFU - GM formation in bone marrow, increased peripheral WBC at 60 min (P <0.05), decreased WBC per unit weight, but did not change significantly in WBC. Conclusion: ATRA can induce the distribution of WBC in peripheral blood in the storage pool of mice. After 15 days of in vivo treatment, the level of GU - GM in bone marrow increased. But not consistent with the phase of WBC changes in clinical APL patients.